Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press179010.17650/1726-9776-2023-19-4-167-175REVIEWSОБЗОРЫEffectiveness and safety of darolutamide as a component of combination therapy in patients with prostate cancerЭффективность и безопасность даролутамида как компонента комбинированной терапии у больных раком предстательной железыhttps://orcid.org/0000-0002-3398-4128AlekseevB. Ya.АлексеевБ. Я.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284,

11 Volokolamskoe Shosse, Moscow 125080

125284 Москва, 2-й Боткинский пр-д, 3,

125080 Москва, Волоколамское шоссе, 11

https://orcid.org/0000-0001-7280-2553PerepukhovV. M.ПерепуховВ. М.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284

25284 Москва, 2-й Боткинский пр-д, 3

https://orcid.org/0000-0002-4171-6211NyushkoK. M.НюшкоК. М.
Russian Federation

Kirill M. Nyushko 

3 2nd Botkinskiy Proezd, Moscow 125284,

11 Volokolamskoe Shosse, Moscow 125080

Нюшко Кирилл Михайлович 

25284 Москва, 2-й Боткинский пр-д, 3,

125080 Москва, Волоколамское шоссе, 11

kirandja@yandex.ruNational Medical Research Radiological Center, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииMedical Institute of Continuing Education, Russian Biotechnological UniversityМедицинский институт непрерывного образования ФГБОУ ВО «Российский биотехнологический университет»2912202319416717529022024290220242023https://oncourology.abvpress.ru/oncur/article/view/1790

Prostate cancer is an extremely important problem in current urologic oncology. For a long time, the golden standard of treatment of common forms of prostate cancer at the stage of distant metastases was androgen deprivation therapy directed at suppression of native testosterone level. Combination treatment using long-term androgen deprivation therapy and new generation antiandrogens is currently a scientifically substantiated conceptually new standard of therapy which has replaced treatment paradigm using androgen deprivation therapy as a monotherapy in patients with metastatic hormone-sensitive prostate cancer. The article presents the results of large trials performed in patients with metastatic hormone-sensitive prostate cancer and characterizes the role of one of the most effective and safe drugs, darolutamide, used to treat patients of this subgroup.

Рак предстательной железы – чрезвычайно актуальная проблема современной онкоурологии. «Золотым стандартом» лечения распространенных форм рака предстательной железы на этапе развития отдаленных метастазов на протяжении длительного времени было проведение андрогендепривационной терапии, направленной на супрессию нативного уровня тестостерона. Комбинированное лечение с применением длительной андрогендепривационной терапии и антиандрогенов новой генерации в настоящее время является научно обоснованным концептуально новым стандартом терапии, пришедшим на смену парадигме лечения с использованием андрогендепривационной терапии в монорежиме у больных метастатическим гормоночувствительным раком предстательной железы. В статье представлены результаты крупных исследований, проведенных у больных метастатическим гормоночувствительным раком предстательной железы, охарактеризована роль одного из наиболее эффективных и безопасных препаратов, даролутамида, применяемого для лечения пациентов данной подгруппы.

darolutamidenonmetastatic castration-resistant prostate cancermetastatic hormone-sensitive prostate cancerhigh progression riskcombination therapydouble combinationtriple combinationдаролутамиднеметастатический кастрационно-рефрактерный рак предстательной железыметастатический гормоночувствительный рак предстательной железывысокий риск прогрессированиякомбинированная терапиядвойная комбинациятройная комбинация1. Шахзадова А.О., Старинский В.В., Лисичникова И.В. Состояние онкологической помощи населению России в 2022 году. Сибирский онкологический журнал 2023;22(5):5–13. DOI: 10.21294/1814-4861-2023-22-5-5-13Шахзадова А.О., Старинский В.В., Лисичникова И.В. Состояние онкологической помощи населению России в 2022 году. Сибирский онкологический журнал 2023;22(5):5–13. DOI: 10.21294/1814-4861-2023-22-5-5-132. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI: 10.1056/NEJMoa040720Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI: 10.1056/NEJMoa0407203. Kyriakopoulos C.E., Chen Y.H., Carducci M.A. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36(11):1080–7. DOI: 10.1200/JCO.2017.75.3657Kyriakopoulos C.E., Chen Y.H., Carducci M.A. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36(11):1080–7. DOI: 10.1200/JCO.2017.75.36574. Fizazi K., Tran N., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352–60. DOI: 10.1056/NEJMoa1704174Fizazi K., Tran N., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352–60. DOI: 10.1056/NEJMoa17041745. Davis I.D., Martin A.J., Stockler M.R. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381(2):121–31. DOI: 10.1056/NEJMoa1903835Davis I.D., Martin A.J., Stockler M.R. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381(2):121–31. DOI: 10.1056/NEJMoa19038356. Armstrong A.J., Szmulewitz R.Z., Petrylak D.P. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormonesensitive prostate cancer. J Clin Oncol 2019;37(32):2974–86. DOI: 10.1200/JCO.19.00799Armstrong A.J., Szmulewitz R.Z., Petrylak D.P. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormonesensitive prostate cancer. J Clin Oncol 2019;37(32):2974–86. DOI: 10.1200/JCO.19.007997. Chi K.N., Agarwal N., Bjartell A. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):13–24. DOI: 10.1056/NEJMoa1903307Chi K.N., Agarwal N., Bjartell A. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):13–24. DOI: 10.1056/NEJMoa19033078. Fizazi K., Foulon S., Carles J. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design. Lancet 2022;399(10336):1695–707. DOI: 10.1016/S0140-6736(22)00367-1Fizazi K., Foulon S., Carles J. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design. Lancet 2022;399(10336):1695–707. DOI: 10.1016/S0140-6736(22)00367-19. Markham A., Duggan S. Darolutamide: first approval. Drugs 2019;79(16):1813–8. DOI: 10.1007/s40265-019-01212-yMarkham A., Duggan S. Darolutamide: first approval. Drugs 2019;79(16):1813–8. DOI: 10.1007/s40265-019-01212-y10. Smith M.R., Hussain M., Saad F. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132–42. DOI: 10.1056/NEJMoa2119115Smith M.R., Hussain M., Saad F. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132–42. DOI: 10.1056/NEJMoa211911511. Bowling G.C., Dimitrakoff J.D. Darolutamide in metastatic prostate cancer. N Engl J Med 2022;386(24):2344. DOI: 10.1056/NEJMc2205310Bowling G.C., Dimitrakoff J.D. Darolutamide in metastatic prostate cancer. N Engl J Med 2022;386(24):2344. DOI: 10.1056/NEJMc220531012. Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737–46. DOI: 10.1056/NEJMoa1503747Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737–46. DOI: 10.1056/NEJMoa150374713. Clarke N.W., Ali A., Ingleby F.C. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial [published correction appears in Ann Oncol 2020;31(3):442]. Ann Oncol 2019;30(12):1992–2003. DOI: 10.1093/annonc/mdz396Clarke N.W., Ali A., Ingleby F.C. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial [published correction appears in Ann Oncol 2020;31(3):442]. Ann Oncol 2019;30(12):1992–2003. DOI: 10.1093/annonc/mdz39614. Fizazi K., Tran N., Fein L. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20(5):686–700. DOI: 10.1016/S1470-2045(19)30082-8Fizazi K., Tran N., Fein L. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20(5):686–700. DOI: 10.1016/S1470-2045(19)30082-815. James N.D., de Bono J.S., Spears M.R. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):338–51. DOI: 10.1056/NEJMoa1702900James N.D., de Bono J.S., Spears M.R. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):338–51. DOI: 10.1056/NEJMoa170290016. Hussain M., Tombal B., Saad F. et al. Darolutamide plus androgendeprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol 2023;41(20):3595–607. DOI: 10.1200/JCO.23.00041Hussain M., Tombal B., Saad F. et al. Darolutamide plus androgendeprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol 2023;41(20):3595–607. DOI: 10.1200/JCO.23.0004117. Preisser F., Chun F.K., Banek S. et al. Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. Prostate Int 2021;9(3):113–8. DOI: 10.1016/j.prnil.2020.12.003Preisser F., Chun F.K., Banek S. et al. Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. Prostate Int 2021;9(3):113–8. DOI: 10.1016/j.prnil.2020.12.00318. Wenzel M., Würnschimmel C., Nocera L. et al. Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis. Eur Urol Focus 2022;8(2):399–408. DOI: 10.1016/j.euf.2021.04.003Wenzel M., Würnschimmel C., Nocera L. et al. Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis. Eur Urol Focus 2022;8(2):399–408. DOI: 10.1016/j.euf.2021.04.00319. Mandel P., Hoeh B., Wenzel M. et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis. Eur Urol Focus 2023;9(1):96–105. DOI: 10.1016/j.euf.2022.08.007Mandel P., Hoeh B., Wenzel M. et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis. Eur Urol Focus 2023;9(1):96–105. DOI: 10.1016/j.euf.2022.08.00720. Sathianathen N.J., Pan H.Y.C., Lawrentschuk N. et al. Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: an updated systematic review and network meta-analysis. Urol Oncol 2023;41(5):233–9. DOI: 10.1016/j.urolonc.2022.10.016Sathianathen N.J., Pan H.Y.C., Lawrentschuk N. et al. Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: an updated systematic review and network meta-analysis. Urol Oncol 2023;41(5):233–9. DOI: 10.1016/j.urolonc.2022.10.01621. Yanagisawa T., Rajwa P., Thibault C. et al. Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur Urol 2022;82(6):584–98. DOI: 10.1016/j.eururo.2022.08.002Yanagisawa T., Rajwa P., Thibault C. et al. Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur Urol 2022;82(6):584–98. DOI: 10.1016/j.eururo.2022.08.00222. Maiorano B.A., de Giorgi U., Roviello G. et al. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. ESMO Open 2022;7(5):100575. DOI: 10.1016/j.esmoop.2022.100575Maiorano B.A., de Giorgi U., Roviello G. et al. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. ESMO Open 2022;7(5):100575. DOI: 10.1016/j.esmoop.2022.10057523. Roy S., Sayyid R., Saad F. et al. Addition of docetaxel to androgen receptor axis-targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: a network metaanalysis. Eur Urol Oncol 2022;5(5):494–502. DOI: 10.1016/j.euo.2022.06.003Roy S., Sayyid R., Saad F. et al. Addition of docetaxel to androgen receptor axis-targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: a network metaanalysis. Eur Urol Oncol 2022;5(5):494–502. DOI: 10.1016/j.euo.2022.06.00324. Mori K., Mostafaei H., Sari Motlagh R. et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network metaanalysis. BJU Int 2022;129(4):423–33. DOI: 10.1111/bju.15507Mori K., Mostafaei H., Sari Motlagh R. et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network metaanalysis. BJU Int 2022;129(4):423–33. DOI: 10.1111/bju.1550725. Chi K.N. LATITUDE study – final analysis of phase III study in patients with newly diagnosed high-risk metastatic castrationnaïve prostate cancer. Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, February 14–16, 2019, San Francisco, CA.Chi K.N. LATITUDE study – final analysis of phase III study in patients with newly diagnosed high-risk metastatic castrationnaïve prostate cancer. Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, February 14–16, 2019, San Francisco, CA.26. Chi K.N., Chowdhury S., Bjartell A. et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 2021;39(20):2294–303. DOI: 10.1200/JCO.20.03488Chi K.N., Chowdhury S., Bjartell A. et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 2021;39(20):2294–303. DOI: 10.1200/JCO.20.0348827. Armstrong A. Final overall survival analysis from ARCHES: a phase 3, randomized, double-blind, placebo-controlled study of enzalutamide + ADT in men with mHSPC. Presented at the 2021 European Society for Medical Oncology Annual Congress, September 16–21, 2021.Armstrong A. Final overall survival analysis from ARCHES: a phase 3, randomized, double-blind, placebo-controlled study of enzalutamide + ADT in men with mHSPC. Presented at the 2021 European Society for Medical Oncology Annual Congress, September 16–21, 2021.28. Gravis G., Boher J.M., Joly F. et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and longterm survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016;70(2):256–62. DOI: 10.1016/j.eururo.2015.11.005Gravis G., Boher J.M., Joly F. et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and longterm survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016;70(2):256–62. DOI: 10.1016/j.eururo.2015.11.00529. James N.D. Abiraterone acetate plus prednisolone for hormonenaïve prostate cancer: long-term results from metastatic (M1) patients in the STAMPEDE randomized trial. Presented at the 2020 European Society for Medical Oncology Virtual Congress, September 19–21, 2020.James N.D. Abiraterone acetate plus prednisolone for hormonenaïve prostate cancer: long-term results from metastatic (M1) patients in the STAMPEDE randomized trial. Presented at the 2020 European Society for Medical Oncology Virtual Congress, September 19–21, 2020.30. Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149–58. DOI: 10.1016/S1470-2045(12)70560-0Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149–58. DOI: 10.1016/S1470-2045(12)70560-031. Dou M., Liang H., Liu Y. et al. Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis. J Cancer Res Clin Oncol 2023;149(10):7017–27. DOI: 10.1007/s00432-023-04658-6Dou M., Liang H., Liu Y. et al. Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis. J Cancer Res Clin Oncol 2023;149(10):7017–27. DOI: 10.1007/s00432-023-04658-632. Borgmann H., Lallous N., Ozistanbullu D. et al. Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201). Eur Urol 2018;73(1):4–8. DOI: 10.1016/j.eururo.2017.08.012Borgmann H., Lallous N., Ozistanbullu D. et al. Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201). Eur Urol 2018;73(1):4–8. DOI: 10.1016/j.eururo.2017.08.01233. Shore N., Zurth C., Fricke R. et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol 2019;14(5):527–39. DOI: 10.1007/s11523-019-00674-0Shore N., Zurth C., Fricke R. et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol 2019;14(5):527–39. DOI: 10.1007/s11523-019-00674-034. Fizazi K., Shore N., Tammela T.L. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer [published correction appears in N Engl J Med 2022;387(9):860]. N Engl J Med 2019;380(13):1235–46. DOI: 10.1056/NEJMoa1815671Fizazi K., Shore N., Tammela T.L. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer [published correction appears in N Engl J Med 2022;387(9):860]. N Engl J Med 2019;380(13):1235–46. DOI: 10.1056/NEJMoa1815671